Transcarent Reviews Liraglutide
Routable as a configured step-therapy rung where downstream partners support it.
Sold as Saxenda, Victoza · Reviewed September 19, 2026
What “Orchestrated” means here
The vendor does not prescribe or dispense. It routes members to a contracted clinical partner and enforces your eligibility policy across them.
The pairing
How Transcarent handles Liraglutide
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- Orchestrated
- Gating
- Employer-configured.
- Prescribes directly
- No
- Step therapy
- Yes
- Prior authorization
- Yes
- Titration protocol
- Not applicable — routes to contracted clinical vendors
- Off-ramp
- Managed through the downstream clinical partner
- Care team
- Care guides, Nurses, Clinical review team
Ask Transcarent this
Which of your downstream partners will actually trial liraglutide first, and can you report compliance with that step by partner?
Watch out
Savings guarantees are measured against a baseline the vendor helps construct. Negotiate the baseline methodology first — it matters more than the guarantee.
The molecule
Liraglutide in one page
The first-generation daily GLP-1. Lower efficacy than the weekly agents, but generic entry has made it the cheapest genuine GLP-1 option and a credible step-therapy rung.
Clinical profile
- Drug class
- GLP-1 receptor agonist
- Brand names
- Saxenda — Chronic weight managementVictoza — Type 2 diabetes
- Mechanism
- Single GLP-1 receptor agonist with a shorter half-life than the weekly agents, requiring daily administration to maintain effect.
- Administration
- Once-daily subcutaneous injection. Daily dosing is the main adherence disadvantage versus weekly agents.
- Titration
- Weekly dose escalation over roughly a month to the maintenance dose — a substantially shorter ladder than the weekly agents.
- Typical result
- Average body-weight reduction in the high single digits as a percentage — roughly half what the newer agents produce, though achieved faster and at a fraction of the cost.
- Generic available
- Yes
Known side effects
- Gastrointestinal effects similar in kind to the weekly agents
- Injection-site reactions somewhat more common given daily administration
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
What benefits teams need to know
This is your step-therapy rung
Generic availability makes liraglutide the only GLP-1 that can sit meaningfully below the weekly agents on cost. A vendor that will genuinely trial it before escalating has a real cost-control mechanism; one that lists it and never uses it does not.
Adherence is the honest tradeoff
Daily injection produces worse persistence than weekly dosing. A step-therapy protocol built on this molecule needs to distinguish members who failed on efficacy from members who failed on adherence, because they warrant different escalation decisions.
Alternatives
Other vendors and Liraglutide
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Omada Health Coaching companion | Companion support | 8.4 | $32–$58 |
| Form Health Full-service clinical | First-line | 8.0 | $58–$105 |
| Teladoc Health Navigation & orchestration | Adjunct | 7.4 | $18–$44 |
| 9amHealth Metabolic specialist | Adjunct | 7.3 | $34–$72 |
| Calibrate Full-service clinical | Adjunct | 7.2 | $65–$110 |
| WeightWatchers Clinic Consumer-brand clinical | Adjunct | 6.9 | $30–$68 |
Same vendor
Transcarent across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
Transcarent neither prescribes nor dispenses. It triages members, routes them to a contracted clinical vendor, and enforces your semaglutide eligibility policy consistently across every downstream partner — which is difficult to do manually across a multi-vendor stack.
Same routing and policy-enforcement posture. The value is consistency: one rule set applied to tirzepatide across every downstream vendor, rather than five vendors interpreting your policy five ways.
Routed through downstream clinical partners as a low-cost first rung within whatever step-therapy policy you configure.